A Phase 2/3 interventional study of Emapalumab and Anakinra in SARS-CoV-2, sponsored by Swedish Orphan Biovitrum. Terminated at 12 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-03-10.
Sponsored by Swedish Orphan Biovitrum · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Hyper-inflammation, caused by a cytokine storm resulting from an exaggerated response of the immune system in the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is considered to represent one of the most important negative prognostic factors in patients infected with sSARS-CoV-2. The objective of this study is to investigate new treatment options to reduce the number of patients requiring mechanical ventilation. This is intended to address the most urgent need to preserve the access to intensive care unit support to the lowest possible number of patients and may potentially reduce mortality.
This is an open label, controlled, parallel group, 3-arm, multicenter study to assess the efficacy and safety of Emapalumab or Anakinra, versus standard of care (SoC). Patients between 30 and 80 years will be eligible to participate in the study. The study is planned to consist of three groups, each comprising 18 patients. Treatment will be randomized to either Emapalumab+SoC, Anakinra+SoC or only SoC for two weeks. Follow-up visit or phone calls will be made 4 and 8 weeks after end of treatment period.
Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of respiratory distress, defined as:
Presence of hyperinflammation defined as:
Lymphocyte counts:
and
i. Ferritin > 500ng/mL
ii. LDH > 300 U/L
iii. D-Dimers > 1000 ng/mL
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Emapalumab i.v. infusion every 3rd day for a total 5 infusions. Day 1: 6mg/kg. Days 4, 7, 10 and 13: 3 mg/kg
Biological: Emapalumab
Anakinra i.v. infusion four times daily for 15 days. 400 mg/day in total, divided into 4 doses given every 6 hours
Biological: Anakinra
Standard of care according to local practice
I.v. infusion every third day
Also known as: Gamifant
Daily i.v. infusion
Also known as: Kineret
Number of Participants With Treatment Success
Defined as the number of patients not requiring invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO)
Time frame: Up to Day 15
Number of Participants Requiring Mechanical Ventilation
Measured in number of participants
Time frame: Date of randomization to date of mechanical ventilation, up to 15 Days
Change From Baseline in Modified Early Warning System Score
The full (unabbreviated) scale name is Modified Early Warning system score (MEWS score) Measured in total score Total score is the sum of 5 categorized components (blood pressure, heart rate, respiratory rate, temperature and alert/voice/pain/unresponsive score) that are assigned a score between 0 and 2 or 0 and 3. MEWS total score range is 0 to 14. Higher score= worse outcome
Time frame: Baseline, Day 15
Change From Baseline in Ferritin
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Lactate Dehydrogenase (LDH)
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in D-dimers
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Resting Peripheral Capillary Oxygen Saturation (SpO2)
Measured in percent (%)
Time frame: Baseline, 3 assessments every Days 4, 7, 10, 13 and 15
Change From Baseline in Oxygen Supplementation
Measured in l/min
Time frame: Baseline, Days 4, 7, 10, 13 and 15.
Change From Baseline in Partial Pressure of Oxygen/Fraction of Inspired Oxygen (PaO2/FiO2)
Measured in mmHg
Time frame: Baseline, Day 15
Number of Participants With Changes in High-resolution Computed Tomography (CT) Scan of the Chest
Measured in scan evaluation: Normal, Abnormal but not clinically significant, Abnormal clinical significant, Not Done
Time frame: Screening, Day 15
Overall Survival
Confirmation of death
Time frame: Weeks 6 and 10
Number of Patients With Hospital Discharge
Measured in number of patients
Time frame: Until discharge up to Week 10
Change of Carbon Dioxide Tension (pCO2) in Hemogasanalysis From Baseline
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change of Oxygen Tension (pO2) in Hemogasanalysis From Baseline
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change of Potassium in Hemogasanalysis From Baseline
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change of Sodium in Hemogasanalysis From Baseline
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change of Chloride in Hemogasanalysis From Baseline
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change of Lactic Acid in Hemogasanalysis From Baseline
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change of Hemoglobin in Hemogasanalysis From Baseline
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in White Blood Cells With Differential Counts
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Red Blood Counts
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Hemoglobin
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Platelet Count
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Fibrinogen
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Complement Factors C3/C4
Measured in local units
Time frame: Day 15
Change From Baseline in Prothrombin Time
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Cardiac Troponin
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Aspartate Aminotransferase (AST)
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Alanine Aminotransferase (ALT)
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Total Bilirubin Levels
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in C-Reactive Protein
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
Change From Baseline in Creatinine
Measured in local units
Time frame: Baseline, Days 4, 7, 10, 13 and 15
| Milestone | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Started | 5 | 5 | 6 |
| Completed | 3 | 4 | 5 |
| Not completed | 2 | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Death | 1 | 1 | 0 |
Defined as the number of patients not requiring invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO)
| Participants | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Number of Participants With Treatment Success | 3 | 4 | 5 |
Measured in number of participants
| Participants | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Number of Participants Requiring Mechanical Ventilation | 1 | 1 | 1 |
The full (unabbreviated) scale name is Modified Early Warning system score (MEWS score) Measured in total score Total score is the sum of 5 categorized components (blood pressure, heart rate, respiratory rate, temperature and alert/voice/pain/unresponsive score) that are assigned a score between 0 and 2 or 0 and 3. MEWS total score range is 0 to 14. Higher score= worse outcome
| scores on a scale | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change From Baseline in Modified Early Warning System Score | -1.00 ± 0.00 | 0.00 ± 0.82 | -0.75 ± 0.96 |
Measured in local units
| pmol/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from Baseline at D4 | -380.8 ± 3026.3 | -2864.2 ± 3789.3 | -770.2 ± 1093.0 |
| Change from Baselind at D7 | 60.5 ± 2503.4 | -2179.6 ± 3108.3 | -1103.3 ± 168.4 |
| Change from Baselind at D10 | -527.5 ± 3086.3 | -2066.8 ± 3342.9 | -1295.0 ± 359.8 |
| Change from Baseline at D13 | -823.1 ± 2792.5 | -1931.1 ± 3601.8 | -1260.6 ± 781.7 |
| Change from baseline at D15 | -506.6 ± 2518.2 | -2045.2 ± 3627.7 | -842.6 ± 1020.0 |
Measured in local units
| U/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from Baseline at D4 | -128.3 ± 160.9 | -31.8 ± 13.0 | -70.4 ± 85.5 |
| Change from Baseline at D7 | -164.3 ± 267.4 | -16.8 ± 162.9 | -96.0 ± 107.3 |
| Change from Baseline at D10 | -184.3 ± 200.2 | -60.4 ± 76.4 | -143.5 ± 128.7 |
| Change from Baseline at D13 | -185.3 ± 260.9 | -2.6 ± 264.4 | -155.0 ± 121.0 |
| Change from Baseline at D15 | -163.6 ± 252.4 | -20.6 ± 274.8 | -158.4 ± 108.3 |
Measured in local units
| nmol/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from Baseline at D4 | -0.19 ± 0.34 | 5.13 ± 14.73 | -2.05 ± 1.65 |
| Change from Baseline at D7 | -7.37 ± 13.84 | 6.78 ± 19.41 | -4.30 ± 1.96 |
| Change from Baseline at D10 | -10.07 ± 18.16 | 4.66 ± 12.82 | -7.18 ± 5.96 |
| Change from Baseline at D13 | -7.99 ± 13.40 | 6.84 ± 19.39 | -5.67 ± 7.11 |
| Change from Baseline at D15 | -6.84 ± 12.67 | 6.64 ± 19.51 | -5.55 ± 6.45 |
Measured in percent (%)
| SpO2% | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | -0.667 ± 3.598 | 0.267 ± 2.060 | 0.722 ± 2.603 |
| Change from baseline at D7 | 0.867 ± 2.923 | 0.667 ± 1.748 | 2.000 ± 2.415 |
| Change from baseline at D10 | 0.625 ± 3.523 | 0.267 ± 1.754 | 2.333 ± 3.528 |
| Change from baseline at D13 | 1.358 ± 2.140 | -2.233 ± 6.098 | 1.600 ± 3.639 |
| Change from baseline at D15 | -1.640 ± 3.383 | -2.400 ± 5.771 | 2.944 ± 2.840 |
Measured in l/min
| L/min | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | 0.0 ± 0.0 | 2.8 ± 5.5 | -0.2 ± 9.5 |
| Change from baseline at D7 | -1.0 ± 5.8 | -1.8 ± 4.8 | -7.8 ± 9.1 |
| Change from baseline at D10 | -3.3 ± 6.9 | -2.3 ± 6.2 | -17.8 ± 18.2 |
| Change from baseline at D13 | -4.3 ± 8.1 | -3.3 ± 7.8 | -20.0 ± 17.0 |
| Change from baseline at D15 | -3.6 ± 9.3 | -4.3 ± 7.9 | -15.3 ± 19.3 |
Measured in mmHg
| mmHg | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change From Baseline in Partial Pressure of Oxygen/Fraction of Inspired Oxygen (PaO2/FiO2) | 28.98 ± 106.66 | 51.19 | 156.72 ± 113.53 |
Measured in scan evaluation: Normal, Abnormal but not clinically significant, Abnormal clinical significant, Not Done
| Participants | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Normal | 0 | 0 | 1 |
| Abnormal (NC) | 1 | 3 | 1 |
| Abnormal (CS) | 3 | 1 | 2 |
Confirmation of death
| Participants | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Overall Survival | 2 | 1 | 0 |
Measured in number of patients
| Participants | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Hospital Discharge | 3 | 4 | 5 |
| Terminated prior to discharge | 2 | 1 | 1 |
Measured in local units
| mmHg | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | 0.00 ± 7.21 | -1.00 ± 3.46 | 2.00 ± 5.77 |
| Change from baseline at D7 | -0.33 ± 9.45 | 1.00 ± 1.41 | 5.46 ± 5.68 |
| Change from baseline at D10 | 2.33 ± 6.03 | 3.67 ± 8.08 | 4.20 ± 5.12 |
| Change from baseline at D13 | 0.30 ± 9.48 | 6.50 ± 3.54 | 0.25 ± 4.11 |
| Change from baseline at D15 | 0.77 ± 8.33 | 3.75 ± 5.74 | 4.00 ± 5.10 |
Measured in local units
| mmHg | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | 19.33 ± 44.28 | 40.67 ± 34.78 | 5.75 ± 16.92 |
| Change from baseline at D7 | 19.33 ± 36.56 | 18.50 ± 13.44 | 23.64 ± 35.04 |
| Change from baseline at D10 | 4.00 ± 37.36 | -1.33 ± 11.93 | 4.00 ± 43.73 |
| Change from baseline at D13 | 18.00 ± 84.85 | -12.00 ± 5.66 | 24.25 ± 36.04 |
| Change from baseline at D15 | 17.57 ± 61.05 | 8.75 ± 47.84 | 8.80 ± 21.37 |
Measured in local units
| mmol/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | 0.55 ± 0.92 | -0.35 ± 0.49 | 0.45 ± 1.34 |
| Change from baseline at D7 | 0.45 ± 1.20 | 0.40 | 0.53 ± 0.93 |
| Change from baseline at D10 | 0.25 ± 0.92 | 0.25 ± 0.49 | 0.43 ± 1.22 |
| Change from baseline at D13 | -0.50 | 0.10 | 0.10 ± 0.85 |
| Change from baseline at D15 | 0.00 ± 0.71 | 0.03 ± 0.75 | 0.17 ± 0.47 |
Measured in local units
| mmol/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | 3.0 ± 5.7 | -0.5 ± 2.1 | -4.5 ± 2.1 |
| Change from baseline at D7 | 1.0 ± 1.4 | -5.0 | 0.3 ± 4.0 |
| Change from baseline at D10 | 2.0 ± 4.2 | -3.0 ± 7.1 | 1.3 ± 1.2 |
| Change from baseline at D13 | -2.0 | -6.0 | -1.0 ± 1.4 |
| Change from Baseline at D15 | 2.5 ± 6.4 | 0.0 ± 2.6 | 0.7 ± 2.1 |
Measured in local units
| mmol/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | 2.0 ± 5.7 | -0.5 ± 2.1 | 1.5 ± 2.1 |
| Change from baseline at D7 | 0.5 ± 0.7 | -4.0 | 2.5 ± 0.7 |
| Change from baseline at D10 | 0.0 ± 2.8 | -4.5 ± 3.5 | 4.0 ± 1.4 |
| Change from baseline at D13 | -1.0 | -4.0 | 3.0 |
| Change from baseline at D15 | 2.0 ± 4.2 | -2.0 ± 3.0 | 3.0 ± 2.8 |
Measured in local units
| mmol/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | 0.20 | 0.00 ± 0.28 | -0.45 ± 1.20 |
| Change from baseline at D7 | 0.70 | 1.80 | 0.00 ± 0.85 |
| Change from baseline at D10 | 0.90 | 1.20 ± 0.17 | -0.50 ± 0.28 |
| Change from baseline at D13 | — | 0.10 | 0.20 |
| Change from baseline at D15 | 0.00 | 1.27 ± 1.16 | -0.05 ± 0.07 |
Measured in local units
| g/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | -34.0 ± 46.7 | -15.5 ± 10.6 | 8.0 ± 2.8 |
| Change from baseline at D7 | -41.0 ± 65.1 | 3.0 | 6.7 ± 1.5 |
| Change from baseline at D10 | -34.0 ± 62.2 | 7.5 ± 6.4 | -1.7 ± 9.5 |
| Change from baseline at D13 | -73.0 | 2.0 | -6.5 ± 20.5 |
| Change from baseline at D15 | -38.0 ± 49.5 | -3.0 ± 18.0 | -4.0 ± 15.9 |
Measured in local units
| 10^9 cells /L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | 1.000 ± 4.408 | 0.294 ± 0.886 | 0.332 ± 3.009 |
| Change from baseline at D7 | 0.340 ± 2.623 | 2.812 ± 2.953 | 1.738 ± 4.165 |
| Change from baseline at D10 | 2.728 ± 1.867 | 4.796 ± 3.091 | 0.806 ± 3.643 |
| Change from baseline at D13 | 1.548 ± 5.265 | 1.588 ± 2.653 | -0.318 ± 4.079 |
| Change from baseline at D15 | 1.686 ± 4.395 | 1.070 ± 2.420 | 1.878 ± 4.788 |
Measured in local units
| 10^12 cells/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | -0.260 ± 0.470 | -0.022 ± 0.351 | -0.108 ± 0.359 |
| Change from baseline at D7 | -0.385 ± 0.732 | 0.016 ± 0.422 | -0.196 ± 0.465 |
| Change from baseline at D10 | -0.415 ± 0.875 | 0.220 ± 0.435 | -0.262 ± 0.549 |
| Change from baseline at D13 | -0.350 ± 1.254 | 0.106 ± 0.395 | -0.275 ± 0.564 |
| Change from baseline at D15 | -0.510 ± 0.969 | 0.004 ± 0.531 | -0.163 ± 0.571 |
Measured in local units
| g/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | -6.2 ± 14.6 | 0.8 ± 7.0 | -3.5 ± 9.1 |
| Change from baseline at D7 | -9.3 ± 21.3 | 0.8 ± 13.1 | -6.2 ± 10.7 |
| Change from baseline at D10 | -11.3 ± 24.5 | 6.6 ± 11.9 | -8.0 ± 16.0 |
| Change from baseline at D13 | -10.8 ± 36.8 | 2.8 ± 13.6 | -8.2 ± 17.3 |
| Change from baseline at D15 | -14.0 ± 28.8 | 0.00 ± 15.6 | -3.7 ± 16.9 |
Measured in local units
| 10^9 cells /L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | 29.0 ± 77.2 | 85.4 ± 76.7 | 9.8 ± 153.7 |
| Change from baseline at D7 | 19.8 ± 116.6 | 140.4 ± 191.8 | 47.4 ± 232.9 |
| Change from baseline at D10 | -3.8 ± 142.5 | 129.8 ± 223.9 | 9.0 ± 232.8 |
| Change from baseline at D13 | -32.0 ± 126.5 | 80.8 ± 213.2 | -53.8 ± 191.9 |
| Change from baseline at D15 | -37.6 ± 129.0 | 41.2 ± 169.3 | -67.2 ± 158.1 |
Measured in local units
| umol/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | -1.435 ± 3.137 | -2.434 ± 1.830 | -0.088 ± 4.582 |
| Change from baseline at D7 | -3.925 ± 6.113 | -4.898 ± 2.610 | -1.147 ± 7.883 |
| Change from baseline at D10 | -3.535 ± 8.998 | -4.980 ± 2.625 | -5.562 ± 5.089 |
| Change from baseline at D13 | -2.587 ± 9.308 | -6.227 ± 2.627 | -5.479 ± 5.027 |
| Change from baseline at D15 | -0.588 ± 9.210 | -6.380 ± 2.357 | -4.596 ± 5.624 |
Measured in local units
| g/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| C3 | 0.054 ± 0.094 | -0.068 ± 0.222 | -0.020 ± 0.581 |
| C4 | 0.024 ± 0.043 | -0.108 ± 0.080 | -0.007 ± 0.192 |
Measured in local units
| sec | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | -0.867 ± 0.058 | 0750 ± 0.071 | -0.550 ± 1.344 |
| Change from baseline at D7 | -1.250 ± 0.071 | 0.300 ± 0.283 | -2.100 |
| Change from Baseline at D10 | -1.003 ± 0.895 | -0.150 ± 0.919 | -1.700 |
| Change from Baseline at D13 | -2.250 ± 0.354 | 0.050 ± 0.495 | -1.600 |
| Change from baseline at D15 | -1.278 ± 1.087 | -0.150 ± 0.778 | -0.800 ± 1.697 |
Measured in local units
| ug/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from Baseline at D4 | -0.017 | — | 0.002 ± 0.002 |
| Change from Baseline at D7 | -0.022 | — | 0.001 ± 0.001 |
| Change from Baseline at D10 | -0.022 | — | -0.001 ± 0.001 |
| Change from Baseline at D13 | -0.021 | — | -0.001 ± 0.001 |
| Change from Baseline at D15 | -0.022 | — | -0.001 ± 0.001 |
Measured in local units
| U/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from baseline at D4 | -46.0 ± 79.8 | -19.2 ± 32.0 | -63.2 ± 146.0 |
| Change from Baseline at D7 | -52.8 ± 107.0 | -27.6 ± 36.8 | -65.4 ± 171.1 |
| Change from Baseline at D10 | -53.3 ± 108.6 | -27.8 ± 32.9 | -79.8 ± 170.6 |
| Change from Baseline at D13 | -44.0 ± 119.3 | -25.2 ± 28.9 | -83.6 ± 163.2 |
| Change from baseline at D15 | -35.4 ± 105.3 | -25.8 ± 28.3 | -77.7 ± 151.0 |
Measured in local units
| U/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from Baseline D4 | -74.8 ± 152.9 | 2.6 ± 38.8 | -23.6 ± 148.8 |
| Change from Baseline D7 | -97.5 ± 237.1 | 16.6 ± 66.9 | -62.0 ± 251.3 |
| Change from Baseline D10 | -107.8 ± 258.3 | 5.0 ± 54.5 | -107.0 ± 350.0 |
| Change from Baseline D13 | -111.0 ± 293.3 | -4.8 ± 51.9 | -119.2 ± 352.2 |
| Change from Baseline at D15 | -90.6 ± 260.7 | -5.8 ± 53.2 | -121.8 ± 309.1 |
Measured in local units
| umol/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from Baseline at D4 | -0.171 ± 3.519 | -1.129 ± 12.314 | 0.376 ± 2.600 |
| Change from Baseline D7 | -1.496 ± 4.011 | -0.376 ± 15.492 | 0.684 ± 9.922 |
| Change from Baseline D10 | -0.385 ± 4.598 | 4.685 ± 21.108 | 0.787 ± 11.931 |
| Change from Baseline D13 | -1.710 ± 4.413 | 13.885 ± 30.276 | 3.591 ± 14.146 |
| Change from Baseline at D15 | -3.523 ± 4.473 | 14.125 ± 29.771 | -0.057 ± 9.046 |
Measured in local units
| mg/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from Baseline D4 | -53.73 ± 98.88 | -20.66 ± 22.29 | -12.65 ± 12.81 |
| Change from Baseline D7 | -63.65 ± 101.74 | -19.20 ± 30.95 | -10.98 ± 19.57 |
| Change from Baseline D10 | -60.05 ± 106.21 | -20.70 ± 30.57 | -14.60 ± 15.72 |
| Change from Baseline D13 | -60.50 ± 106.66 | -8.26 ± 50.51 | -16.33 ± 14.27 |
| Change from Baseline D15 | -38.96 ± 103.48 | -8.32 ± 50.53 | -15.26 ± 12.71 |
Measured in local units
| umol/L | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Change from Baseline D4 | -6.542 ± 9.430 | 1.414 ± 8.516 | -6.041 ± 8.148 |
| Change from Baseline D7 | -8.840 ± 14.454 | 0.530 ± 6.893 | 0.000 ± 6.156 |
| Change from Baseline D10 | -7.514 ± 14.481 | 0.000 ± 5.830 | -0.530 ± 5.506 |
| Change from Baseline D13 | -5.304 ± 20.171 | 0.000 ± 8.928 | -1.945 ± 3.088 |
| Change from Baseline D15 | -9.901 ± 19.281 | -0.354 ± 9.756 | -5.746 ± 24.292 |
Collected over All fatal and life-threatening SAEs occurring after study drug initiation and up to the end of study visit (Visit 9, Week 10) were reported. All adverse event data were collected from Day 1 to follow-up Week 10.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Emapalumab | 2/5 (40%) | 2/5 (40%) | 1/5 (20%) |
| Anakinra | 1/5 (20%) | 1/5 (20%) | 1/5 (20%) |
| Standard of Care | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| End-stage respiratory failureRespiratory, thoracic and mediastinal disorders | 2/5 | 0/5 | 0/6 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/5 | 1/5 | 0/6 |
| Event | Emapalumab | Anakinra | Standard of Care |
|---|---|---|---|
| Atrial FibrillationCardiac disorders | 1/5 | 0/5 | 0/6 |
| Muscle HematomaMusculoskeletal and connective tissue disorders | 1/5 | 0/5 | 0/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/5 | 1/5 | 0/6 |
| HypertransaminasaemiaHepatobiliary disorders | 0/5 | 0/5 | 1/6 |
| Age, Continuous(years) | Emapalumab | Anakinra | Standard of Care | Total |
|---|---|---|---|---|
| Mean | 65.0 ± 14.8 | 62.4 ± 11.1 | 62.5 ± 62.5 | 63.3 ± 12.3 |
| Sex: Female, Male(Participants) | Emapalumab | Anakinra | Standard of Care | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 0 | 2 |
| Male | 4 | 4 | 6 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Emapalumab | Anakinra | Standard of Care | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 2 |
| Not Hispanic or Latino | 4 | 3 | 5 | 12 |
| Unknown or Not Reported | 0 | 1 | 1 | 2 |
| Region of Enrollment(participants) | Emapalumab | Anakinra | Standard of Care | Total |
|---|---|---|---|---|
| Italy | 5 | 5 | 6 | 16 |
| Hospitalization(Participants) | Emapalumab | Anakinra | Standard of Care | Total |
|---|---|---|---|---|
| Count of participants | 5 | 5 | 6 | 16 |
| Height (cm)(cm) | Emapalumab | Anakinra | Standard of Care | Total |
|---|---|---|---|---|
| Mean | 170.8 ± 10.9 | 170.2 ± 4.4 | 172.3 ± 14.4 | 171 ± 9.5 |
| Weight (kg)(kg) | Emapalumab | Anakinra | Standard of Care | Total |
|---|---|---|---|---|
| Mean | 77.4 ± 15.0 | 79.4 ± 13.4 | 83.0 ± 12.8 | 79.7 ± 13 |
| Symptom duration (days)(days) | Emapalumab | Anakinra | Standard of Care | Total |
|---|---|---|---|---|
| Mean | 4.0 ± 4.2 | 1.0 ± 0 | 5.3 ± 4.8 | 3.6 ± 4.0 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2020 to primary completion in Nov 2020, 7 months.
Results were first posted in Mar 2022, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Emapalumab · Interleukin 1 Receptor Antagonist Protein